|
|
 |
|
Viewing report
|
|
|
|
Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1
Renub Research, June 2010, Pages: 114
“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:
- Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
- Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
- Region wise Diabetes Health Expenditure and Mortality
- Top 10 Countries Diabetes Population and Future Forecast
- Top 5 Countries Diabetes Drug Market and Future Forecast
- Top 7 Countries Insulin Market and Future Forecast
- Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
- Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
- Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
- Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market
Research Highlights:
- USA controls more than 50% of the total Diabetes Drug market share in 2009
- Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
- China will have the second highest Insulin market share by 2012 replacing Germany
- DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
- GLP-1 Agonists, market is forecast to cross US$ 6 Billion mark by 2015
- Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
- Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
- Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
- Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
- China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
- Japan Insulin market is expected to be more than US$ 1 Billion by 2010
Key Drugs Analyzed:
Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus, GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide
Data Sources:
Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class
DPP IV Inhibitors - Global Strategic Business Report
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
Diabetes Market Forecast to 2015
Non-Insulin Diabetes. Management Products, Players, Markets, and Forecasts
Canada Diabetes Market Report & Forecast 2011-2016
World Insulin Management Systems Market
Turkey Diabetes Market Report & Forecast 2011-2016
Brazil Diabetes Market Report & Forecast 2011-2016
Competitor Analysis: Diabetes Drug Pipeline
|
|
|
|
